Transmission of familial Mediterranean fever mutation after bone marrow transplantation and successful treatment with anakinra.
Petropoulou
Anna D
AD
Robin
Marie
M
Socié
Gérard
G
Galicier
Lionel
L
D000741:Anemia, Aplastic / Q000601:surgery; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D016572:Cyclosporine / Q000627:therapeutic use; D010505:Familial Mediterranean Fever / Q000188:drug therapy / Q000235:genetics*; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007258:Informed Consent; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D008297:Male; D009154:Mutation; D013318:Stroke Volume; D014184:Transplantation, Homologous / Q000009:adverse effects; D016896:Treatment Outcome; D055815:Young Adult
D000900:Anti-Bacterial Agents; D000961:Antilymphocyte Serum; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D053590:Interleukin 1 Receptor Antagonist Protein; D016572:Cyclosporine